AAN 2019 Coverage

During a migraine attack, experiencing nausea with and without vomiting is associated with nonadherence to acute migraine medication guidelines.

Researchers sought to determine whether combining memantine with a cholinesterase inhibitor produced early and consistent improvements in cognition for patients with moderate to severe Alzheimer disease.

Older men with type 2 diabetes who received metformin or newer hypoglycemic medication had less cognitive decline compared with those who received sulfonylureas.

Use of zonisamide showed long-term efficacy for Parkinsonism and dementia with Lewy bodies without deterioration of cognitive function.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may represent effective migraine prophylactic treatments.

Long-term adjunctive treatment with amantadine may enable the levodopa regimen to be optimized in patients with Parkinson experiencing motor complications.

An expert subcommittee of the AAN has released an updated evidence-based clinical practice guideline on treating Tourette syndrome and other chronic tic disorders.

Results from a study evaluating the safety and efficacy of suvorexant (Merck) for the treatment of insomnia in patients with mild to moderate Alzheimer disease dementia were presented at the 2019 American Academy of Neurology Annual Meeting. The phase 3 placebo-controlled trial included 277 patients who were randomized to receive either suvorexant 10mg (which could…

Serious infections related to treatment with rituximab in patients with multiple sclerosis are rare and successfully resolvable.

Droxidopa is associated with better treatment adherence than midodrine when medication cost is noninfluential.